QNCX (Quince Therapeutics) Long-Term Debt: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

QNCX Quince Therapeutics Inc QNCX
25 GF Score
Price $23.03
! 2 Warning Signs
View Full Analysis

What is Quince Therapeutics Long-Term Debt?

Quince Therapeutics QNCX 25 Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates QNCX with a GF Score™ of 25/100. The stock has 2 warning signs investors should review.

Quince Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Quince Therapeutics's annual Long-Term Debt increased from Dec. 2023 ($13.43 Mil) to Dec. 2024 ($14.32 Mil) but then declined from Dec. 2024 ($14.32 Mil) to Dec. 2025 ($0.00 Mil).

Quince Therapeutics  (NAS:QNCX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Quince Therapeutics Long-Term Debt Related Terms

Quince Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Quince Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quince Therapeutics Long-Term Debt Chart

Quince Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 13.43 14.32 0.00

Quince Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.27 16.99 0.00 0.00 0.00
QNCX
25GF Score
Quince Therapeutics Inc QNCX
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Quince Therapeutics (QNCX) has a Long-Term Debt of $0.00 Mil as of Mar. 2026.
Is Quince Therapeutics' Long-Term Debt too high?
Quince Therapeutics' current Long-Term Debt is $0.00 Mil. Overall, Quince Therapeutics has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Quince Therapeutics' Long-Term Debt compare to LPCN and NXTC?
Quince Therapeutics' Long-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Quince Therapeutics's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quince Therapeutics stock overvalued right now?
Quince Therapeutics (QNCX) has a current Long-Term Debt of $0.00 Mil. The current Long-Term Debt is $0.00 Mil. Quince Therapeutics' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Quince Therapeutics (QNCX), the current Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Quince Therapeutics Business Description

Address 611 Gateway Boulevard, Suite 273, South San Francisco, CA, USA, 94080
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
25GF Score

Get the complete analysis for QNCX

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.03
Price